---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-092914"
form_type: "8-K"
ticker: null
cik: "0001261249"
company_name: "AGILE THERAPEUTICS INC"
filed_at: "2024-08-26T23:59:59+00:00"
generated_at: "2026-05-31T07:35:26.343841+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Agile Therapeutics acquired by Insud Pharma for $1.52/share, total enterprise value ~$45M

## Summary
- Shareholders approved merger on Aug 22, 2024; deal closed Aug 26, 2024.
- Each Agile share converted to $1.52 cash; total enterprise value ~$45M.
- Agile common stock to cease trading on OTCQB; company becomes indirect subsidiary of Insud.
- All directors and officers resigned; new board chaired by Salustiano Pérez, Robert Spina as CEO.
- Outstanding equity awards cancelled; RSUs converted to cash at same $1.52 per share.

## SEC filing metadata
- accession: 0001104659-24-092914
- form_type: 8-K
- cik: 0001261249
- company_name: AGILE THERAPEUTICS INC
- filed_at: 2024-08-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 5.07, 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1261249/000110465924092914/0001104659-24-092914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1261249/000110465924092914/tm2422458d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-092914
- JSON: https://secwatch.observer/filing/0001104659-24-092914.json
- Plain text: https://secwatch.observer/filing/0001104659-24-092914.txt

## Key facts
- M&A Transactions
  AGILE THERAPEUTICS INC underwent a change of control involving Insud Pharma, S.L. (closed 2024-08-26).
  - Action: change of control
  - Counterparty: Insud Pharma, S.L.
  - Closing: 2024-08-26
  source text: on August 26, 2024 (the “Closing Date”) of the transactions (the “Closing”) contemplated by that certain Agreement and Plan of Merger (the “Merger Agreement”), dated as of June 25, 2024, by and among Insud Pharma, S.L., a company existing under the laws of Spain (“Insud”), Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud (“Merger Sub”), and Agile Therapeutics, Inc., a Delaware corporation (“Agile” or the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1261249/000110465924092914/0001104659-24-092914-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.